Feature | January 02, 2014

St. Jude Medical Gains CE Mark for 25 mm Portico Transcatheter Aortic Heart Valve

st. jude portico transcatheter aortic heart valve repair hybrid or
January 2, 2014 — St. Jude Medical Inc. received European CE mark approval for its 25 mm Portico Transcatheter Aortic Heart Valve Implantation System. The approval expands the number of patients who can be treated using the Portico heart valve during transcatheter aortic valve replacement (TAVR) procedures.
 
“The fact that the Portico valve is repositionable prior to valve deployment helps ensure accurate placement, potentially improving patient outcomes,” said Axel Linke, M.D., University of Leipzig, Germany, and investigator in the Portico Transfemoral CE Mark Trial (Portico TF CE Trial).
 
Made of bovine pericardial tissue attached to a self-expanding stent frame, the Portico valve is the first transcatheter aortic heart valve that can be completely resheathed, repositioned at the implant site or retrieved before being released from the delivery system.
 
“The Portico valve is an important part of our growing portfolio of products that treat valvular disease and heart failure. The approval of this 25 mm valve size will allow us to expand our footprint in the global TAVR market and provide a promising solution for patients with severe aortic stenosis,” said Frank Callaghan, president, cardiovascular and ablation technologies division, St. Jude.
 
The 25-mm Portico valve supports a patient’s native annulus with diameters ranging from 21 to 23 mm. With the addition of the 25 mm valve, the Portico platform can now treat patients with an annulus ranging from 19 to 23 mm. In 2014, St. Jude Medical expects to add two additional valve sizes to the Portico line, which will expand the eligible range of patients to those with annulus sizes ranging from 19 to 27 mm.
 
During an implant procedure, the Portico valve is delivered through a catheter after a small incision is made to the femoral artery in the leg. Positioned while the patient’s heart continues to beat, use of the Portico valve alleviates the use cardiopulmonary bypass.
 
The Portico 23- and 25-mm transcatheter aortic heart valves continue to be evaluated in a non-randomized, multicenter study, the Portico TF CE Trial. Data from this study was recently presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Results highlighted the valves’ hemodynamic performance and improvement in the severity of patients’ heart failure symptoms as measured by the New York Heart Association (NYHA) Functional Classification System. The 23 mm Portico Transcatheter Aortic Heart Valve received CE mark November 2012. The Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System are not approved for use in the United States.
 
For more information: www.sjmportico.com

Related Content

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Edwards Lifesciences, completes acquisition, Valtech Cardio
News | Heart Valve Technology| January 25, 2017
Edwards Lifesciences Corp. announced that it has closed its acquisition of Valtech Cardio Ltd., developer of the...
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart| January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
TAVR, medical guidelines, ACC/AHA, optimization, transcatheter aortic valve replacement
News | Heart Valve Technology| January 18, 2017
The American College of Cardiology recently released new guidance for clinicians and hospitals to use in assessing...
Medtronic, CoreValve Evolut R 34 mm valve, TAVI, CE Mark, European launch
News | Heart Valve Technology| January 17, 2017
Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve...
Tendyne Mitral valve

The Tendyne mitral valve being implanted. 

News | Heart Valve Technology| January 16, 2017
January 16, 2017 – In 2015, researchers and physicians at the Minneapolis Heart Institute Foundation (MHIF) were the
BioTrace Medical, first U.S. patients, Tempo Temporary Pacing Lead, EP lab, TAVR
News | Leads Implantable Devices| January 13, 2017
BioTrace Medical Inc. announced in December the first commercial use of the company’s Tempo Temporary Pacing Lead since...
RECHORD Trial, Neochord DS1000 System, mitral regurgitation, PinnacleHealth, first Pennsylvania patient
News | Heart Valve Technology| January 06, 2017
The RECHORD trial allows cardiovascular surgeons to replace damaged string-like tendons, called chordae, through a...
Hitachi, Vector Flow Mapping, TedMed 2016, Partho Sengupta, holographic evaluation of cardiac valves
News | Cardiovascular Ultrasound| January 04, 2017
January 4, 2017 — A new ground-breaking technology that allows evaluation of...
Overlay Init